key: cord-0279665-iteu7qhm authors: Meyer, M.; Constancias, F.; Worth, C.; Meyer, A.; Muller, M.; Boussuge, A.; Kaltenbach, G.; Schmitt, E.; Chayer, S.; Velay, A.; Vogel, T.; Fafi-Kremer, S.; Karcher, P. title: Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds. date: 2021-11-19 journal: nan DOI: 10.1101/2021.11.19.21266252 sha: 0a4b6115c134b9b8ace14a1856d47b637a720bb0 doc_id: 279665 cord_uid: iteu7qhm INTRODUCTION The objectives of this study were to assess the dynamics of the SARS-CoV-2 anti-RBD IgG response over time among older people after COVID-19 infection or vaccination and its comparison with speculative levels of protection assumed by current data. METHODS From November 2020 to October 2021, we included geriatric patients with serological test results for COVID-19. We considered antibody titre thresholds thought to be high enough to protect against SARS-CoV-2 infection: 141 BAU/ml for protection/vaccine efficacy > 89.3%. Three cohorts are presented. A vaccine group (n=34) that received two BNT162b2/Comirnaty injections 21 days apart, a group of natural COVID-19 infection (n=32) and a third group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection (n=17). RESULTS 83 patients were included, the median age was 87 (81-91) years. In the vaccine group at 1 month since the first vaccination, the median BAU/ml with IQR was 620 (217-1874) with 87% of patients above the threshold of 141 BAU/ml. Seven months after the first vaccination the BAU/ml was 30 (19-58) with 9.5% of patients above the threshold of 141 BAU/ml. In the natural COVID-19 infection group, at 1 month since the date of first symptom onset, the median BAU/ml was 798 (325-1320) with 86.7% of patients above the threshold of 141 BAU/ml and fell to 88 (37-385) with 42.9% of patients above the threshold of 141 BAU/ml at 2 months. The natural infection group was vaccinated three months after the infection. Five months after the end of the vaccination cycle the BAU/ml was 2048 (471-4386) with 83.3% of patients above the threshold of 141 BAU/ml. DISCUSSION On the humoral level, this supports the clinical results describing the decrease in vaccine protection over time. France 25 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266252 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266252 doi: medRxiv preprint No specific funding was received for this work. 48 49 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 19, 2021. ; https://doi.org/10.1101/2021.11.19.21266252 doi: medRxiv preprint The objectives of this study were to assess the dynamics of the SARS-CoV-2 anti-RBD IgG 52 response over time among older people after COVID-19 infection or vaccination and its 53 comparison with speculative levels of protection assumed by current data. 54 From November 2020 to October 2021, we included geriatric patients with serological test 56 results for COVID-19. 57 We considered antibody titre thresholds thought to be high enough to protect against SARS-58 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The results in the different groups as a function of time are shown in Figure 1 and Table S1 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The data are medians (with interquartile range) for the study of Anti-RBD IgG titers and for the temporal expression of the parameter studied.The data are effectives for description of sample size. The data are percentages for the expression of theoretical protection of patients with antibody titer above the suggested threshold. Performance of the 182 rapid high-throughput automated electrochemiluminescence immunoassay targeting total 183 antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the 184 neutralization assay Correlates of protection against symptomatic and 187 asymptomatic SARS-CoV-2 infection Antibody titers and 190 protection against a SARS-CoV-2 infection WHO International Standard for anti-193 SARS-CoV-2 immunoglobulin Differential Kinetics of Immune Responses 196 Elicited by Covid-19 Vaccines Waning Immunity after the BNT162b2 Vaccine in Israel